Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-109 in Advanced Solid Tumors and Sarcomas
NCT03715933Phase 1Recruiting
- Sponsor
- Inhibrx Biosciences
- Start
- Oct 2018
- Primary completion
- Dec 2028
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of ozekibart in solid tumor, Ewing sarcoma, colorectal adenocarcinoma and 4 more (14 arms), sponsored by Inhibrx Biosciences. Primary endpoints: Frequency and severity of adverse events up to 8 years and Tumor Response up to 8 years. Started Oct 2018; status: recruiting.
02
Drugs
ozekibart
03
Conditions
solid tumorEwing sarcomacolorectal adenocarcinomamalignant pleural mesothelioma (MPM)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03715933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715933.